Unstoppable Dividend King for 2022: AbbVie or Johnson & Johnson?
AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) have plenty of similarities. They're both large-cap stocks in the healthcare space that are also Dividend Kings. Both appear to be undervalued based on their current and expected future earnings. They're the type of steady, long-term investments that retirees and other investors could love. Yet one of these two, in my view, is a better bet as an unstoppable stock in 2022. Let's take a closer look.
Johnson & Johnson had revenue of $82.5 billion last year, more than the gross domestic product of many countries. And the company keeps growing. Over the past five years, J&J has increased revenue each year -- or some 27% in total during that period.
Source Fool.com